Medication info

Sitagliptin Metformin Tablets 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride with Colloidal Anhydrous Silica›505mg / 1 tablet
Manufacturer / importer
NBK Pharmaceutical Co., Ltd.
Appearance
Bright pink oval film-coated tablet
Packaging
30 tablets/box [10 tablets/PTPX3]
Approval status
Active

MFDS item code 202200908 · Approved 2022.03.02

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medicine should be based on the patient’s current treatment regimen. 1. Patients not currently treated with metformin: For patients with no prior experience with diabetes drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is one 50/500 mg tablet twice daily. The dose may be increased to one 50/1000 mg tablet twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2, “Patients who must not receive this medicine,” under Precautions for Use). 2. Patients treated with metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may begin with their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see section 5, “General precautions,” under Precautions for Use). No studies have evaluated the safety and efficacy of switching patients previously treated with another oral glucose-lowering agent to this medicine. Any change in treatment for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2, “Patients who must not receive this medicine,” under Precautions for Use).

Ingredients

Manufacturer
NBK Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood sugar control
View approved original text

This medication assists in controlling blood glucose levels for patients with type 2 diabetes, complementing dietary and exercise regimens. It is used alone for those without prior experience of diabetes medication who find it challenging to control blood sugar. It can also be used in place of monotherapy with metformin or sitagliptin when adequate blood glucose control is not achieved or in the case of dual therapy with both medications. If blood glucose is not controlled, it can be combined with sulfonylureas, thiazolidinediones, or insulin to enhance therapeutic effect. This medication provides assistance to patients struggling to manage blood sugar through various medications.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medicine should be based on the patient’s current treatment regimen. 1. Patients not currently treated with metformin: For patients with no prior experience with diabetes drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is one 50/500 mg tablet twice daily. The dose may be increased to one 50/1000 mg tablet twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2, “Patients who must not receive this medicine,” under Precautions for Use). 2. Patients treated with metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may begin with their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see section 5, “General precautions,” under Precautions for Use). No studies have evaluated the safety and efficacy of switching patients previously treated with another oral glucose-lowering agent to this medicine. Any change in treatment for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2, “Patients who must not receive this medicine,” under Precautions for Use).

Precautions

This medication is used for diabetes treatment and contains two active ingredients, sitagliptin and metformin. While taking this medication, severe allergic reactions may occur; therefore, if symptoms such as skin rash or respiratory distress appear, discontinue use immediately and consult a physician. Serious side effects have been reported, including acute pancreatitis, which is inflammation of the pancreas, so if symptoms such as abdominal pain or vomiting occur during treatment, notify medical personnel immediately. Patients with severely impaired kidney function, heart failure, or acute myocardial infarction should not use this drug, and it should be discontinued before and after examinations using iodine contrast agents. It is safe for pregnant women or those who might become pregnant, as well as nursing women, not to take this medication. This medication may cause hypoglycemia, so blood glucose levels should be monitored closely, especially when taken with insulin or sulfonylureas. Furthermore, this medication may lead to lactic acidosis, a rare but life-threatening metabolic complication. If sudden symptoms such as respiratory distress, muscle pain, or fatigue occur, notify medical personnel immediately. Regular kidney function and blood tests are recommended during treatment, as vitamin B12 deficiency may occur. Alcohol consumption may increase the risk of side effects from this medication; therefore, excessive drinking should be avoided while on treatment. In cases of undergoing surgery, discontinue use 48 hours prior to the procedure and restart only after confirming normal kidney function. During treatment, regular meals, exercise, and consistent blood glucose testing should be maintained according to the physician's directives.

Side effects

anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory tract infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, severe and disability-associated arthralgia, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rash, urticaria, cutaneous vasculitis, elevated liver enzymes, acute renal failure, dyspnea, unstable angina, dizziness, decreased appetite, gastrointestinal disturbance, itching, severe hypoglycemia, increased serum creatinine, anemia, dermatitis, weight loss

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a sealed container to prevent the entry of air or moisture, preferably at a temperature between 1 to 30 degrees Celsius. This way, the medication's effectiveness can be well-maintained.

Appearance and packaging

Appearance

Bright pink oval film-coated tablet

Package unit

30 tablets/box [10 tablets/PTPX3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.